
Image: This Is Engineering [CC BY-NC-ND 2.0], via Flickr
Unfunded projects lost out on more than £3bn as a result, says Bioindustry Association
Early stage biomedical companies have collectively missed out on half a billion pounds of investment from the UK government over the past three years, despite being judged to be of high-enough quality to be funded, according to an analysis of internal data.
Data obtained by BIA though a freedom of information (FOI) request, and shared exclusively with Research Professional News, show that fewer than 4 per cent of projects ranked as being worthy of investment through the Biomedical Catalyst programme ended up receiving funding in 2019-20, down from 31 per cent in 2014-15.